LIVZON PHARMA (01513): The application for the market approval of Leconqitumab Injection has been accepted by the National Medical Products Administration.

China National Medicines Corporation announced that its controlling subsidiary, Zhuhai Lizhu Monoclonal Antibody Biotechnology Co., Ltd. ("Lizhu Monoclonal Antibody"), has received the "Acceptance Notice" (Acceptance Number: CXSS2500144) issued by the National Medical Products Administration. The application for the domestic production and marketing registration of the Lekangqita Monoclonal Antibody Injection developed jointly by Lizhu Monoclonal Antibody and Beijing Xinkanghe Biotechnology Co., Ltd. has been accepted by the National Medical Products Administration.